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■ LETTER TO THE EDITOR ■
Squamous cell carcinomas (SCCs) account for approxi-
mately 80% of cervical cancers, adenocarcinomas 15%
and adenosquamous carcinomas 3% to 5%. There are
some rare variants of malignancy arising from the uter-
ine cervix, such as neuroendocrine or small cell carci-
nomas, rhabdomyosarcoma in adolescents and young
women, and primary cervical lymphoma and sarcoma.
The major risk factors for cervical cancer include
early onset of sexual activity, multiple sexual partners,
and a high-risk sexual partner. These factors imply the
probability of human papillomavirus (HPV) infection,
and HPV is strongly associated with the development
of cervical cancer. HPV 16 is the dominant type in SCC;
however, HPV 18 is more frequently seen in adenocar-
cinoma [1,2]. Other risk factors are a history of sexually
transmitted diseases, smoking, high parity, immunosup-
pression, low socioeconomic status, prolonged use of
oral contraceptives, and a previous history of vulvar or
vaginal squamous dysplasia.
Disease stage is the most important prognostic fac-
tor of cervical cancer, followed by lymph node status.
Women with stage IB or IIA disease with negative pelvic
lymph nodes have a 5-year survival of 88% to 96%,
compared with 64% to 74% for those with similar stage
of disease and pelvic nodal metastasis [3]. Some series
support that adenocarcinomas have the same 5-year
survival rate when adjusted for stage [4–6]. However,
other studies also pointed out the higher rate of distant
metastases in patients with adenocarcinoma [7].
Clear cell adenocarcinoma (CCAC) accounts for ap-
proximately 3% to 10% of adenocarcinomas of the uter-
ine cervix [8]. Primary cervical CCAC generally occurs
in young women with in utero exposure to diethylstilbes-
trol (DES), which is prescribed to pregnant women 
to prevent abortion [9,10]. Here, we present a case of
CCAC of the uterine cervix without such a predisposing
factor.
A 62-year-old, gravida 2, para 2, postmenopausal
woman denied any major systemic disease, such as hy-
pertension, diabetes or cardiac disease. She had never
received any Pap smear before. She visited the gynecol-
ogic clinic because of painless menopausal bleeding for
1 month. A indurated cervical tumor was noted. Pap
smear and cervical biopsy were performed. The result
of cervical cytology was normal. However, the histo-
pathology by punch biopsy revealed CCAC. The patient
could not recall any in utero exposure to DES even
though she was thoroughly questioned. She was then
referred to our hospital. Pelvic examination showed a
uterus in the atrophic state with no obvious cervical
lesion, except for the biopsy wound. Bilateral parame-
tria were free of tumor invasion as determined by
pelvic examination. Levels of the tumor markers were
all within normal ranges: CA-125 22.3 U/mL (normal,
< 35 U/mL) and CEA 0.69 ng/mL (normal, < 2.5 ng/
mL). HPV test was performed with cervical scraping, and
it revealed positive HPV type 18. Pelvic and abdominal
magnetic resonance imaging showed a solid cervical
tumor around 1.5 cm in diameter. No definite hydro-
nephrosis or abnormal enlarged pelvic or para-aortic
lymph nodes could be identified. Cystoscopy revealed
no evidence of tumor invasion of the urinary bladder.
The patient underwent a radical abdominal hysterec-
tomy, bilateral salpingo-oophorectomy, and bilateral
pelvic lymph node dissection under the impression of
stage IB1 cervical CCAC. A 2-cm tumor inside the 
posterior cervical wall with intact endocervical canal
was identified macroscopically. The pathologic report
showed a CCAC composed mainly of marked dysplastic
cells with clear or eosinophilic cytoplasm and focally
present hobnail nuclei arranged in a tubulocystic pat-
tern (Figure A). Hyaline globules could be noted focally.
Perivascular invasion was also seen (Figure B). All of the
pelvic lymph nodes were free from tumor metastasis.
The bilateral parametria and vaginal cuff were also not
invaded by the tumor. Because of the deep stromal and
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perivascular invasion, adjuvant radiotherapy was given.
She was followed up at our clinic and lived without
disease for 6 months.
CCAC is a rare variant of cervical malignancy. CCAC
may involve any organ, from ovary to vagina. It is thought
to be related to in utero exposure of DES, which is pre-
scribed to pregnant women to prevent abortion. How-
ever, CCAC does occur without in utero exposure to
DES. Hanselaar and colleagues reported that among
73 cases of CCAC born after 1947, there were 26 (32%)
without exposure to DES [11]. The age distribution
showed two peaks. One was at the young age ranging
from 17 to 37 years (mean, 26 years), and the other 
at the older age ranging from 44 to 88 years (mean, 
71 years). This bimodal age distribution was attrib-
uted to the cases with DES exposure at the first peak.
However, in Japan, where DES has not been prescribed
to pregnant women, the age at diagnosis ranged from
0 to 79 years with a mean age of 50.8 years, and there
were no separate peaks in the age distribution [12].
The age at diagnosis in our case was 63 years. There
was no obvious history of the exposure to DES for our
patient.
In addition to in utero exposure to DES, HPV infec-
tion [13], bcl-2 protein overexpression [14] and p53
gene mutation [15] are also important. Waggoner et al
reported HPV type 31 infection detected in cases of
CCAC of the vagina and cervix. However, the impor-
tance of this infection was not elucidated. Our patient
was infected with HPV type 18. This correlated with the
most prevalent type observed in cervical adenocarci-
noma [1,2], but not with Waggoner et al’s observation.
Waggoner et al also found p53 protein expression in
14 of 21 cases (67%). It was suggested to be a response
to generalized DNA damage. On the other hand, bcl-2
overexpression was observed in 18 of these 21 patients.
Their hypothesis supported that overexpression of 
bcl-2 can inhibit p53-mediated apoptosis and suggests
a mechanism by which these rare tumors can arise
without mutation of the p53 gene.
Management of early-stage cervical adenocarcinoma
includes radical hysterectomy plus pelvic lymphadenec-
tomy or definitive radiation therapy. High-risk factors
for recurrence include positive pelvic lymph nodes, posi-
tive parametrial extension, and positive vaginal margins.
In patients with these high risk factors, chemoradia-
tion is the postoperative adjuvant treatment of choice
[16]. In patients with at least the two following risk
factors, postoperative radiation therapy could decrease
recurrent rate with acceptable morbidity: capillary lym-
phatic space invasion with more than one-third stromal
invasion, and larger tumor [17].
Stage, tumor size, growth pattern, nuclear atypia,
and mitotic activity are important prognostic factors
[11]. An unfavorable prognosis is associated with high
stage, a large tumor, nuclear atypia, and high mitotic
activity. In cervical adenocarcinoma, most of the pa-
tients were diagnosed at stage I or II, but their 5-year
survival rate was only 55.7% and was poorer than that
of the SCC counterparts. Reich et al analyzed 15 CCACs
in women not exposed to DES in utero [18]. The clini-
copathologic findings and prognosis of these patients
were similar to those with SCCs and non-CCAC. How-
ever, the incidences of parametrial involvement and
metastatic pelvic lymph node were 40% and 47%, respec-
tively. Early recurrence and distant metastasis were
observed in patients with positive pelvic nodes. There
were two risk factors (i.e. lymphovascular permeation
and deep stromal invasion) for our patient after radical
hysterectomy, and she underwent adjuvant radiother-
apy. Although there is no definitive evidence showing a
poorer prognosis of CCACs than SCCs, early recurrence
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Figure. (A) Marked dysplastic cells with clear or eosinophilic cytoplasm and focally present hobnail nuclei (arrow) arranged
in a tubulocystic pattern. (B) Clear cell adenocarcinoma with perivascular invasion (arrow) was also noted. (A, B: hematoxylin
and eosin, 400×.)
and distant metastasis have been observed. We rec-
ommend that patients with cervical CCAC should be
treated more aggressively.
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